Idorsia Ltd.

December 9, 2021
img: Featured

Neurocrine Biosciences acquired the global rights to NBI-827104 from Idorsia in May 2020. NBI-827104 is an investigational, selective, orally active, brain penetrating T-type calcium channel blocker (Cav 3.1, Cav 3.2, Cav 3.3) for the potential treatment of epileptic encephalopathy with continuous spike-and-wave during sleep (EE-CSWS). We are also developing NBI-827104 for the potential treatment of essential tremor. The agreement also includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates.